Dyson V8 Plus Cordless Vacuum Is Now One of the Best Early Prime Day Deals at Its Lowest Price Yet
If you can afford to make your chores a little bit easier, then you definitely deserve to do so. After all, none of us really enjoys having to deal with dishes, cat litter, dusting, or vacuuming. Well, maybe you do, and that's good for you, but for most of us, it's a constant slog of tasks that never really ends. That's why it's for the best that you have the right tools.
See at Amazon
Today, we've found an excellent deal on a really great vacuum that should make it easier than ever to get rid of dust, pet hair, and anything else your floor ends up dealing with. The Dyson V8 Plus is a cordless vacuum that'd normally cost you an eye-watering $470, but thanks to a 26% discount, you can currently nab it for $350. There's no way of knowing how long this deal will last though, so if you do like the look of this vacuum, we recommend acting quickly to avoid the disappointment of missing out.
Suck It Up
The Dyson V8 Plus is incredibly lightweight at just 2.6kg, which means it's a lot easier to move around on standard floors, but it also means that you'll be able to tackle stairs or out-of-reach spots more easily. It also means that those who aren't as strong as they used to be can still get a lot of use out of it, which is good if you're buying this for an older relative or someone else.
It's got a decent battery life too, and can last up to 40 minutes between charges, which should be enough to get most homes done without issue. The motorbar cleaner also helps it actively clean the floor and dig up stubborn things like long hair or pet fluff, which is a huge win if you've got shaggier carpets or shaggier pets.
It even comes with four different heads to choose from to help you better hit tricky areas or more niche use-cases as well. It's all about making everything that little bit easier, and that's what tech should do when it can.
While worth it, the standard price of $470 is undoubtedly pretty hard for most people to manage. However, the $120 discount makes it far better value for money. There's no way of knowing how long a deal like this will last though, which is why we recommend snatching it up if you want it and can afford it.
See at Amazon
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Could Investing $10,000 in CoreWeave Make You a Millionaire?
CoreWeave has emerged as a new AI stock to watch. The company launched its initial public offering in March, and the stock already has soared in the triple digits. 10 stocks we like better than CoreWeave › Investors have piled into artificial intelligence (AI) stocks over the past couple of years, especially big names such as AI chip leader Nvidia or cloud giant Amazon. Though these companies have helped shareholders score a major win quarter after quarter and could continue to climb, some investors now are looking beyond these names that have constantly been on center stage. They aim to find the next big AI success story, and one that has emerged in recent times is CoreWeave (NASDAQ: CRWV). This tech company is new to the market, having launched its initial public offering in March, and the stock already has soared more than 320% from that point. Investors are excited about this new AI investing opportunity, especially considering the company has been delivering triple-digit revenue growth. Could investing $10,000 in CoreWeave make you a millionaire? Let's find out. So, first, let's talk a little bit about this new-to-the-market company that's outperformed well-established tech giants such as the Magnificent Seven companies so far this year. CoreWeave actually is closely linked to the world's most talked-about AI company, Nvidia, and this may be part of the reason why investors are so excited about its future. This company's main business is offering customers access to its giant fleet -- 250,000 to be exact -- of Nvidia chips across more than 30 data centers. These graphics processing units (GPUs) may be rented for long periods of time or simply by hour, offering customers great flexibility for their AI workloads. Since demand has been extremely high, even surpassing supply, for Nvidia's latest Blackwell architecture and chip, investors clearly are optimistic about CoreWeave's prospects too. CoreWeave even was the first to make this new architecture generally available to customers, highlighting its ability to serve customers fast with the latest innovations. And the fact that market giant Nvidia holds a 7% stake in CoreWeave is another element that could appeal to investors. Nvidia's backing suggests this young company is set to play a key role in the next phases of the AI story. A look at CoreWeave's growth so far shows great momentum, with revenue soaring more than 400% in the first quarter. And even considering uncertainties in recent months that have pressured the stock market, CoreWeave says customer demand still increased. In fact, the big challenge right now is to scale up and meet demand. This requires significant investment, and that means investors should expect spending to increase moving forward. Of course, CoreWeave faces competition from traditional cloud service providers, but the company stands out because it truly specializes in handling AI workloads, and doing this at scale. This could work to CoreWeave's advantage as demand for compute-intense inferencing accelerates. Now, let's get back to our question: Could investing $10,000 in CoreWeave make you a millionaire? It's clear that CoreWeave offers an interesting growth story at the moment, and even after its spectacular gains could make a compelling buy for long-term growth investors who can handle some risk. But even if CoreWeave goes on to climb 1,000% over the coming years, as tech companies have been known to do, your $10,000 would reach $110,000. This would be fantastic, but it's far from $1 million. Before making any investment decisions, though, it's important to keep in mind that you shouldn't count on any one stock to make you a millionaire. It's extremely rare to succeed this way, and even worse, it's high risk. You have a much better chance of reaching the $1 million mark, and avoiding disastrous losses, if you invest in a diversified portfolio of quality stocks. So, for example, if $10,000 is your investing budget, split this amount across several stocks and at least a few industries. And the great news is you can apply the same technique with any amount. Now, in this context, a purchase of CoreWeave could help you along the road to wealth and even eventually nudge your portfolio toward the value of $1 million. Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool's board of directors. Adria Cimino has positions in Amazon. The Motley Fool has positions in and recommends Amazon and Nvidia. The Motley Fool has a disclosure policy. Could Investing $10,000 in CoreWeave Make You a Millionaire? was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
Tesla's robotaxi ambitions face a reality check after launch
For Elon Musk, tech's great showman, this weekend's long-awaited launch of a Tesla robotaxi service will be notably short of Sign in to access your portfolio
Yahoo
41 minutes ago
- Yahoo
Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time
Investors often gravitate to companies announcing and completing forward stock splits. In 2025, only a small number of high-profile companies have effected historic splits -- but every one of these businesses has proved their worth to Wall Street. The market's latest stock-split stock, which completed a unique 38-for-1 forward split earlier this week, has no sale or product and is a disaster waiting to happen. 10 stocks we like better than Regencell Bioscience › Since the S&P 500's bull market began in October 2022, no trend has provided a bigger lift to equities than the evolution of artificial intelligence (AI). In Sizing the Prize, the analysts at PwC estimated AI would bolster the worldwide economy to the tune of $15.7 trillion come 2030. However, AI isn't the only reason Wall Street's major indexes keep climbing. In addition to the long-term potential AI brings to the table, investor euphoria surrounding stock splits in high-flying companies has kept the stock market's engine humming along. A stock split is a mechanism publicly traded companies have at their disposal which allows them to cosmetically alter their share price and outstanding share count by the same magnitude. These adjustments are surface-scratching in the sense that stock splits don't affect a company's market cap or its operating performance. Although splits can increase (reverse split) or decrease (forward split) a company's share price, there's a clear delineation as to which variety of split investors typically gravitate to. Reverse splits that boost a company's share price and concurrently reduce its outstanding share count by the same factor are often avoided by investors. This type of split is usually undertaken by companies that are struggling on an operating basis and completing their split in an effort to avoid delisting from a major U.S. stock exchange. On the other hand, companies that conduct forward splits are generally sought after by investors. If a company has to lower its share price to make its stock more nominally affordable for retail investors who can't purchase fractional shares with their broker, it's often doing something right. This "something" comes in the form of superior operational execution and top-tier innovation. But as you're about to see, not all forward stock-split stocks are necessarily great businesses. Last year, more than a dozen prominent stocks announced and completed a forward split, many of which can be traced to the technology sector and the artificial intelligence revolution. This includes the face of the AI movement, Nvidia, as well as one of the newest members of the trillion-dollar club, Broadcom. In 2025, only a small number of high-profile companies have announced and completed stock splits. But the one factor they all have in common is they don't hail from the tech sector. Wholesale industrial and construction supplies company Fastenal (NASDAQ: FAST) was the first to actually complete its split (2-for-1) following the close of trading on May 21. It's the ninth time Fastenal has split its stock over the last 37 years. The reason splits have become part of Fastenal's corporate culture is because its stock, including dividends, has increased in value by more than 210,000% since its initial public offering in 1987. This is a reflection of Fastenal's strong cyclical ties to the U.S. economy, as well as its innovation, which has allowed it to become ingrained in the supply chains of America's leading industrial companies. Following Fastenal's lead was auto parts supplier O'Reilly Automotive (NASDAQ: ORLY), which effected a 15-for-1 forward split following the end of trading on June 9. O'Reilly's split reduced its nominal share price from nearly $1,400 to around $90. On top of having one of Wall Street's most-effective share-repurchase programs -- O'Reilly Automotive has spent $25.9 billion to buy back more than 59% of its outstanding shares since the start of 2011 -- the company is benefiting from the aging of America's cars and light trucks. In the latest annual report from S&P Global Mobility, the average age of cars and light trucks on U.S. roadways hit a record 12.8 years in 2025. As vehicles age, drivers and mechanics are becoming more reliant on auto parts chains like O'Reilly. The other preeminent company that announced and completed a forward split in 2025 is electronic automated brokerage firm Interactive Brokers Group (NASDAQ: IBKR). It effected its first-ever split (4-for-1) after the closing bell on June 17. Interactive Brokers' aggressive investments in technology and automation, coupled with the positive impact long-lasting bull markets have had on investors, have virtually all of its key performance indicators pointing higher by a double-digit percentage. It's enjoying double-digit year-over-year growth in total accounts, equity on its platform, and trading activity. While all three of these businesses have proven their worth to Wall Street, the same can't be said about Wall Street's latest stock-split stock, which is eventually going to implode. Following the close of trading on Friday, June 13, clinical-stage traditional Chinese medicine (TCM) company Regencell Bioscience Holdings (NASDAQ: RGC) put a 38-for-1 forward stock split into effect. This split was designed to reduce Regencell's share price from $595 to less than $16 per share, all while increasing its outstanding share count by a factor of 38. The magnitude of this split (38-for-1), coupled with Regencell's year-to-date gain of 60,120% (that's not a typo!), as of the closing bell on June 17, would suggest that it's an operating marvel -- but this couldn't be further from the truth. Since commencing its operations in 2015, Hong-Kong-based Regencell hasn't generated a cent in revenue, nor does it have in any products remotely close to being commercialized, based on its regulatory filings. But this hasn't stopped the company's valuation from soaring to nearly $39 billion. During fiscal 2024, which ended on June 30, Regencell had $4.74 million in operating expenses, no sales, and ultimately reported a comprehensive loss of $4.32 million. It ended its fiscal year with (drum roll) 12 employees, only four of which are involved with research and development and one tied to sales (despite a complete lack of products). Here's a snippet of one of the more pertinent risk factors for the company: Our operations to date have been limited to organizing and staffing our company, partnering with the TCM Practitioner to conduct research studies, identifying potential partnerships and TCM formulae candidates, acquiring TCM raw materials, and conducting research and development activities for our TCM formulae candidates. We have not yet demonstrated the ability to successfully complete large-scale, pivotal research studies. We have also not yet applied for or obtained regulatory approval for, or demonstrated an ability to manufacture or commercialize, any of our TCM formulae candidates. Furthermore, Regencell's risk factors point to there being no guarantees that the company can successfully patent and/or protect its TCM products from third-party claims or even breaches of intellectual property agreements (not covered by patents) with its own employees. But wait -- there's more! With the company extremely early in its development process, sporting no sales, and having no virtually no possibility of sustained positive operating cash flow anytime soon, it also brings a going concern warning to the table. A "going concern warning" effectively means the company's current assets aren't expected to be sufficient to cover its current liabilities over the next 12 months. If you're wondering how a clinical-stage healthcare company with no sales or products skyrockets more than 60,000% in less than six months and executes one of the largest forward splits we've witnessed this decade, your guess is as good as mine. Though borrow rates to short-sell (i.e., bet against) Regencell stock have shot into the stratosphere in recent days, overall short interest has been muted, which removes the notion of this move being propelled by a short squeeze. More than likely, we've witnessed momentum-based risk-takers pile into what had been (prior to its 38-for-1 split) a relatively low-float stock. With more than 494 million shares now outstanding and the company's abysmal fundamental picture in plain sight, it's simply a matter of time before this fairy tale bubble implodes and shares plummet back below $1. Caveat emptor! Before you buy stock in Regencell Bioscience, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Regencell Bioscience wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Sean Williams has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Interactive Brokers Group and Nvidia. The Motley Fool recommends Broadcom and recommends the following options: long January 2027 $175 calls on Interactive Brokers Group and short January 2027 $185 calls on Interactive Brokers Group. The Motley Fool has a disclosure policy. Prediction: Wall Street's Latest Stock-Split Stock -- Up 60,120% Year-to-Date -- Is Going to Implode... It's Just a Matter of Time was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
